Renal cell carcinoma MRI: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Shanshan Cen (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Renal cell carcinoma}} | {{Renal cell carcinoma}} | ||
{{CMG}} | |||
==Overview== | |||
an MRI may be used to diagnose and for follow-up of renal cell carcinoma. | |||
==MRI== | |||
Similar to CT, an MRI may be used to diagnose and for follow-up of renal cell carcinoma. Due to the use of IV gadolinium in MRI, the risk of nephrogenic systemic fibrosis (NSF) must always be considered.<ref name="pmid23665399">{{cite journal| author=Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH et al.|title=Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. | journal=J Urol | year= 2013 | volume= 190 | issue= 2 | pages= 407-16 | pmid=23665399|doi=10.1016/j.juro.2013.04.121 | pmc=|url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23665399 }}</ref> It is a rare condition that often has cutaneous manifestations, but may affect any organ. Risk factors for development of NSF are as follows<ref name="pmid23665399">{{cite journal| author=Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH et al.|title=Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. | journal=J Urol | year= 2013 | volume= 190 | issue= 2 | pages= 407-16 | pmid=23665399|doi=10.1016/j.juro.2013.04.121 | pmc=|url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23665399 }}</ref>: | Similar to CT, an MRI may be used to diagnose and for follow-up of renal cell carcinoma. Due to the use of IV gadolinium in MRI, the risk of nephrogenic systemic fibrosis (NSF) must always be considered.<ref name="pmid23665399">{{cite journal| author=Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH et al.|title=Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. | journal=J Urol | year= 2013 | volume= 190 | issue= 2 | pages= 407-16 | pmid=23665399|doi=10.1016/j.juro.2013.04.121 | pmc=|url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23665399 }}</ref> It is a rare condition that often has cutaneous manifestations, but may affect any organ. Risk factors for development of NSF are as follows<ref name="pmid23665399">{{cite journal| author=Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH et al.|title=Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. | journal=J Urol | year= 2013 | volume= 190 | issue= 2 | pages= 407-16 | pmid=23665399|doi=10.1016/j.juro.2013.04.121 | pmc=|url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23665399 }}</ref>: | ||
*High dose of gadolinium-based contrast | *High dose of gadolinium-based contrast | ||
Revision as of 19:38, 24 August 2015
|
Renal cell carcinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Renal cell carcinoma MRI On the Web |
|
American Roentgen Ray Society Images of Renal cell carcinoma MRI |
|
Risk calculators and risk factors for Renal cell carcinoma MRI |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
an MRI may be used to diagnose and for follow-up of renal cell carcinoma.
MRI
Similar to CT, an MRI may be used to diagnose and for follow-up of renal cell carcinoma. Due to the use of IV gadolinium in MRI, the risk of nephrogenic systemic fibrosis (NSF) must always be considered.[1] It is a rare condition that often has cutaneous manifestations, but may affect any organ. Risk factors for development of NSF are as follows[1]:
- High dose of gadolinium-based contrast
- Acute and chronic renal failure
- Vascular injury
| Patient Profile | Use of MRI | Evidence Strength |
| Low Risk Patient (pT1, N0, Nx) | Baseline abdominal MRI (or CT) for nephron sparing surgery and CT (or US or MRI) for radical nephrectomy within 3-12 months following renal surgery Additional MRI (or US or CT) may be performed in patients following radical nephrectomy if initial post-op baseline image is negative |
Expert opinion C |
| Moderate to High Risk Patients (pT2-4N0 Nx or any stage N+) | Baseline chest and abdominal MRI (or CT) within 3-6 months following surgery with continued imaging (US, CXR, CT, or MRI) every 6 months for at least 3 years and annually thereafter to 5 years. Site specific imaging is warranted by clinical symptoms suggestive of recurrence or metastatic spread. Imaging (US, CXR, CT, or MRI) beyond 5 years may be performed at the discretion of the clinician | C |
| Active surveillance | Cross-sectional abdominal scanning (CT or MRI) within 6 months of active surveillance initiation to establish a growth rate. Further imaging is recommended at least annually thereafter | C |
| Ablation | Patients undergo cross-sectional CT or MRI with and without IV contrast unless contraindicated at 3 and 6 months following ablative therapy to assess treatment success. Annual abdominal CT or MRI should follow for 5 years. Individual MRI (or CT) beyond 5 years is based on individual patient risk factors | C |
References
- ↑ 1.0 1.1 1.2 Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH; et al. (2013). "Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline". J Urol. 190 (2): 407–16. doi:10.1016/j.juro.2013.04.121. PMID 23665399.